PAP Therapy Reduces Hospitalizations by 31% and ER Visits by 23% for People with Obstructive Sleep Apnea and Comorbid Insomnia

Core Insights - ResMed presented 13 new clinical studies at SLEEP 2024, highlighting the effectiveness of Positive Airway Pressure (PAP) therapy for treating Obstructive Sleep Apnea (OSA) and its impact on sleep health [4] Group 1: Clinical Research Findings - A study indicated that adherence to PAP therapy is linked to fewer hospital visits among patients with OSA and comorbid insomnia (COMISA), showing all-cause hospitalizations per person at 0.09 for adherent patients compared to 0.13 for non-adherent patients, and emergency room visits at 0.46 versus 0.60 respectively [2] - Research on the prevalence of insomnia across the Americas found that approximately 17% of adults experience insomnia, emphasizing the need for prioritizing sleep health in public health initiatives [5] - An analysis of over 345,000 adults with OSA revealed that 25.5% of those with depression were women, and those with depression showed lower adherence to PAP therapy, particularly among women [7] Group 2: Company Overview - ResMed is focused on pioneering innovative solutions that treat chronic diseases, including sleep apnea and COPD, through digital health technologies and cloud-connected medical devices, aiming to improve quality of life and reduce healthcare costs [8]